The Greater Cannabis Company skyrocketed on a high turnover of traded shares on announcing a breakthrough of its licensed technology EPP. The company has confirmed completion of development and reformulation of the eluting patch EPP technology.
The eluting patch was developed for pharmaceuticals as well as for over the counter products and other oral health applications. The company has already completed all the necessary testing of formulations in preparation of the commercial launch of its products. The technology has already proved to have the ability to afford consumers a safe alternative to other cannabinoid delivery systems.
Commercialization Drive
Buoyed by the results of the tests so far and the potential of the EPP technology, The Greater Cannabis Company has started ramping up efforts to commercialize the technology. The company is eying sublicenses as well as joint venture agreements. Target partners include licensed cannabis producers in the U.S Canada as well as abroad.
The Greater Cannabis Companies is also eyeing deals with pharmaceutical companies planning to leverage cannabinoid therapies. The sole focus is bringing the technology to market through collaborations that have the potential to generate long-term value.
“Our shareholders should know that our attention is being placed where it should be, on building long-term shareholder value by growing the business and generating revenues. Our objective is to achieve business success, and as such we have no intention of being distracted by day to day stock price, or message boards,” said CEO Mr. Aitan Saccharin, CEO of Greater Cannabis.
